Scopus Biopharma

Scopus Biopharma Net Debt

The Net Debt of Scopus Biopharma (SCPS) as of Nov 19, 2026 is 451,631.00 USD.

Net Debt

451,631.00USD

Last updated:

Net Debt of Scopus Biopharma is 2020 451,631.00 USD. Net Debt of Scopus Biopharma was 2019 - USD. It decreases by % lower compared to the previous year.

The Scopus Biopharma Net Debt history

The Scopus Biopharma Net Debt history
YEARNet DebtYoY
451,631.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scopus Biopharma Stock analysis

What does Scopus Biopharma do? Scopus Biopharma Inc develops therapeutics targeting diseases with unmet medical needs, focusing on immuno-oncology programs. The company's Duet Platform utilizes bifunctional oligonucleotides to activate antigen-presenting cells and alleviate tumor immunosuppression. DUET-01 is in development for relapsed or refractory B-cell non-Hodgkin lymphoma, while DUET-02 targets solid tumors like prostate or kidney cancers through systemic delivery. The firm's products are developed for clinical trials and potential future commercialization. Scopus Biopharma's revenue streams are not disclosed in the business description, but the company is developing its Duet Platform products for potential licensing or partnership agreements. The immuno-oncology focus and bifunctional oligonucleotide platform represent the core of the company's product pipeline. The company's products target specific cancer types with unmet medical needs, aiming to jump-start T cell-mediated immune responses. The company's development pipeline includes DUET-01 for B-cell non-Hodgkin lymphoma and DUET-02 for solid tumors. The Duet Platform's three bifunctional oligonucleotides (DUET-01, DUET-02, DUET-03) form the foundation of its therapeutic approach. The firm is developing these products for potential commercialization after successful clinical trials and regulatory approvals. Scopus Biopharma is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scopus Biopharma stock

Net Debt of Scopus Biopharma is 451,631.00 USD in 2020.

On Eulerpool you can find the complete historical development of Net Debt Scopus Biopharma since 2006 – with annual values, charts, and detailed analysis.

Net debt is total debt minus cash and cash equivalents. It shows the actual debt burden after accounting for available liquid resources.

Net Debt's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Net Debt's Scopus Biopharma historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Scopus Biopharma

All Key Metrics — Scopus Biopharma